A collaborative study has been carried out to establish the precision and accuracy of five test systems for the assessment of the toxicity of whole cell pertussis vaccine. To this end, six vaccines, including both ''normal'' and ''abnormal'' products with respect to arbitrary levels of Pertussis toxin and/or potency were tested. The study included in vivo test systems as the Mouse Weight Gain (MWG) test; the current WHO-recommended bioassay to evaluate overall pertussis toxicity and four specific test systems; the Leukocytosis Promotion (LP) test, the Histamine Sensitization (HS) test and in vitro the Chinese Hamster Ovary (CHO) clustering test to estimate pertussis toxin (PT) levels, and the Limulus Amoebocyte Lysate (LAL) test to evaluate endotoxin levels. In addition, participants were also asked to estimate potency by the Mouse Protection test according to Kendrick (MP). Fourteen laboratories in various countries participated in the study.
Introduction
According to WHO, 1 EP 2 and U.S. 3 requirements for whole cell pertussis vaccine, product-related toxicity should be assessed in the Mouse Weight Gain (MWG) test. This test can be considered as a general, non-specific test measuring overall toxicity since a number of toxins produced during the growth of pertussis organisms may affect the weight gain of mice. Furthermore, other factors not related to the product under test, such as strain of mice used 4 and conditions of housing and microbiological status 5, 6 may influence the result. Correlation of results of the MWG with adverse reactions in children has been claimed. 7, 8, 9, 10 In the requirements reported in the WHO Technical Report Series (TRS) 800, 11 manufacturers are encouraged to measure, in addition to overall toxicity by the MWG test, at least one other substance contributing to the toxicity of the final product; (1) Heat-labile (dermonecrotic) Toxin (HLT); (2) Pertussis toxin (LP, HS); or (3) Endotoxin (LPS). Although adenylate-cyclase toxin (ACT) and Tracheal cytotoxin (TCT) may also contribute to whole cell pertussis toxicity, these toxins are not mentioned in the WHO TRS 800. 11 It should be emphasized that measuring one of the aspects of pertussis toxicity as stated in the WHO TRS, does not give information on the other factors contributing to pertussis toxicity.
During a WHO workshop ''On the In Vitro Control of Bacterial Vaccines'' held in Bilthoven autumn 1990 at the National Institute of Public Health and the Environment (RIVM), it became clear that no information was available about the precision and accuracy of test systems to determine specific toxic effects of whole cell pertussis vaccine, nor did criteria and requirements exist to interpret the results of such a test.
It was decided to organize a collaborative study to evaluate some in vitro and in vivo test systems which are used for the assessment of toxicity of whole cell pertussis vaccine. The study was focused on PT and endotoxin. Apart from HLT, these are the main toxins that can influence the toxicity of whole-cell pertussis vaccine as measured by the MWG test. Both ''normal'' and ''abnormal'' vaccines with respect to arbitrary levels of toxicity and/or potency were included in the study.
The selected tests were:
(1) Mouse Weight Gain (MWG) test;
(2) Leukocytosis Promotion (LP) test; In addition, the Mouse Protection (MP) test according to Kendrick was selected in the collaborative study to evaluate the reproducibility of the test. All participants were asked which tests they were willing to perform using their own standard operating procedures and their own materials and laboratory animals. Due to the complexity of some of the tests and the limited quantity of some of the vaccines, participants were requested to perform only those tests in which they had at least two years experience. The tests performed by the various participants are summarized in Table 1 .
Materials and methods

Mice
Different lines of mice, both inbred and outbred, were used by the participants, originating from local sources. Specifications, when available, are given under Materials and methods for each test separately.
Vaccines
Six vaccines each named by a code were involved in this study having different properties of toxicity and/or potency. The specifications are given in Table 2 .
In order to further characterize the products a Pertussis toxin (PT) binding ELISA was performed at the co-ordinating laboratory to determine PT levels of the various products. In short, two-fold dilutions of the products were preincubated with mAb anti-S4 227 (RIVM) 1:200 000 in phosphatebuffered saline with 0⋅1% Tween (PBST). The preincubation mixtures were transferred to ELISA plates coated with PT (Sclavo). Binding of free mAb to the coat was visualized with Sheep anti-mouse IgG, 1:5000 in PBST (unpublished results).
Methods
Participants used their own operating procedures. A general test design description is given. Local variations per test system are summarized in separate tables.
Mouse weight gain test (MWG)
In the MWG, a volume of the vaccine under study was administered intraperitoneally into a group of mice. Another group of animals received an equal volume of sterile saline for baseline values. Animals were observed for 7 days and body weight was recorded. Weight changes from the initial weight on day 3 are given as absolute changes. Weight changes on day 7 were expressed as percentages of the saline group. Data on the MWG test were obtained from 12 laboratories. Procedure specifications for the participants are presented in Table 3 . According to the WHO and EP requirements, vaccines were considered satisfactory when: (1) the total weight of the mice from the vaccine group 3 days after treatment was the same or higher than the initial weight;
(2) at the end of seven days the average weight gain of the vaccine group was not less than 60% of the control (saline) group; and (3) not more than 5% of the animals died during the test period.
Leukocytosis promotion test (LP)
The leukocytosis promoting activity of vaccines was determined by comparing the number of circulating leukocytes in test and control mice. To this end, groups of mice were injected subcu- Table 1. Review of tests performed and vaccines tested by participants   Laboratory  Vaccine  Test  1  2  3  4  5  6  7  8  9  10 11 12 13 14 taneously, intraperitoneally or intraveneously, with serial dilutions of the preparation under study and the reference preparation respectively. As a negative control, a group of animals was injected with sterile saline only. Three to six days after injection blood samples were collected from the tailvein. For each dilution of vaccine 2-10 mice were used. The number of circulating leukocytes per cubic millimetre of blood was counted with a Coulter Counter, Sysmex or by hand with a haemocytometer and microscope. For purpose of this study the LP activity was expressed in an LP-index, being the average number of leukocytes of the vaccine under study divided by the average number of leukocytes of the undiluted reference preparation (Vaccine C) ×100.
The index was calculated for the undiluted vaccine concentration and the sub-highest vaccine concentration. The LP test was performed by eight laboratories. Differences in procedures are presented in Table 4 .
Histamine Sensitisation test (HS)
In the HS test, groups of mice (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) were injected intraperitoneally with serial dilutions of the vaccine to be tested. Four to 5 days after injection animals were challenged intraperitoneally with 0⋅5 ml of diluted histamine solution and the number of non-surviving mice in a prescribed observation period was recorded. The HS activity is given as the percentage non-surviving animals per group. For this study, results of the highest and sub-highest vaccine dose were used. The HS test was performed by seven participants. Procedure differences are given in Table 5 . 
Chinese Hamster Ovary clustering test (CHO)
In the CHO test, Chinese Hamster Ovary cells were cultured in wells of disposable micro plates. First a two-fold dilution range of the vaccines were made and next CHO-cells were added. After 48 h incubation in a 5% CO 2 atmosphere at 37°C, the clustering effect of the cells was observed under an inverted microscope and the grade of clustering was scored. The highest dilution of the tested vaccine showing total cell clustering is considered to represent the titre. In order to estimate the results of the CHO test, vaccine C was used as a reference preparation. Results are expressed in a relative figure, being the CHO-index which is the end-point titre of the vaccine under study divided by the titre of the reference preparation (Vaccine C) ×100. The CHO test was performed by 5 participants. Variations in procedure are summarized in Table 6 .
Limulus Amoebocyte Lysate endotoxin test (LAL)
Products were tested for endotoxin in the LAL test by eight participants. A volume of the test specimen and lysate were added in pyrogen free tubes or micro plates. A negative control and an endotoxin standard were included in the study. Between-laboratory variation occurred with regard to the lysate used, the definition of end-point and the formation of a firm gel (LAL ''gelation''). In six laboratories the end-point was detected by gelclotting, in one laboratory by spectrophotometric measurement of a change in chromogenic peptide substrate (''chromogenic peptide''), and one laboratory did not specify the end-point.
Mouse Protection test according to Kendrick (MP)
Groups of mice were immunized intraperitoneally with serial dilutions of the test vaccine or the reference preparation. Vaccine E was used as reference preparation, apart from laboratory 8 which used an in-house reference preparation. Intracerebral challenge at day 14 or 15 was done with the strain of Bordetella pertussis customarily (BP 18323) used in the individual laboratories. The number of non-surviving animals from the 4th till the 14th day after challenge were recorded. Based on the percentage of surviving mice per vaccine dose, the potency of the test vaccine (including 95% confidence intervals) was calculated by means of probit analysis. Table 7 summarizes the participants variations in the Mouse Protection test. Data on vaccine potency was obtained from 12 participants.
Results
Study design
Fourteen laboratories, national control authorities as well as manufacturers, from 13 countries took part in this study. Participants who returned results are listed in the Annex. Throughout this report participants are referred by code in random order.
All participants were asked to do only those tests in which they were experienced. Due to the limited Table 1 and Table 2 . Participants were requested to perform tests on at least two occasions (except HS which was tested only once) according to their own standard procedure. Data sheets for raw data and test specifications were provided together with infor-mation on storage conditions and reconstitution procedure.
For each test system data were tested for homogeneity between laboratories by analysis of variance (ANOVA) at P Q 0⋅05, using mean estimates of products tested and standard deviation of mean. Data of duplicate tests were combined using the arithmetic mean of individual tests. Intralaboratory consistency was only assessed by ANOVA (P Q 0⋅05) when duplicate testings were performed. 
*Results in grams, relative to day 0. Lab. 10.1: mice of the saline control were short of water, therefore one mouse died. Lab. 12: one mouse died on day 3 in vaccine A; one mouse died on day 3 in vaccine C. Lab. 14.1: one mouse died on day 1 in vaccine F. The power of each test system to discriminate between products of different toxicity or potency was tested by ANOVA (P Q 0⋅05), using for each product mean data generated by participating laboratories and standard deviation of mean.
Mouse Weight Gain test (MWG)
Test data were received from 12 laboratories. Eight participants examined all preparations, the other participants tested a limited number of products. The MWG was performed in duplicate by all participants except laboratory 12. Data of laboratory 10 could not be used. The mean weight changes at day 3 for each vaccine and each laboratory are given in Table 8 . Data of the MWG at day 7 as assessed in the different laboratories are presented in Figure 1 . Viewed in terms of WHO and EP specifications, vaccine A and C failed to pass the requirement for average weight gain at 72 h in laboratory 12 and vaccine A, B and C did not meet the requirement for relative weight at day 7 in laboratory 5. In a number of tests, one or more than one animal died at participants 5, 6, 9, 12 and 14, which ultimately would have resulted in a rejection of the test. The lowest mean relative weight gain at day 7 was found for vaccine B, the highest relative weight gain for vaccine D and F. The pattern of weight gain varied between the laboratories, laboratory 14 showed a consistent tendency to high weight gain while laboratory 5 and 12, although data of only three products was obtained, consistently produced lower estimates than the other laboratories. Analysis of MWG data at day 7 of those products which were tested in all participating laboratories (products A, B and C) showed a statistical significant interlaboratory variation (P = 0⋅000). Statistical analysis of MWG data in each individual laboratory showed that the various vaccine products were considered to be of a homogeneous population, with the exception of laboratory 8. In this laboratory, P Q 0⋅05 was caused by product B and to a lesser degree by product C and E.
Leukocytosis Promotion test (LP)
Data were obtained from six participants for all vaccines and from two participants for three vaccines. Interlaboratory variation in test performance was observed with regard to the strain and number of mice used, the number of vaccine dilutions used, the day of blood collection and the counting procedure (Table 4 ). Vaccine activity in the LP test is plotted for the undiluted (highest vaccine dose) product and the 1/2 diluted product (sub-highest vaccine dose) in Figure 2 . For the highest vaccine dose analysis of intralaboratory variation at duplicate testing showed statistical significant differences for participant 6 (P = 0⋅041) and 8 (P= 0⋅005) but not 4 (P = 0⋅888) and 14 (P = 0⋅472). Interlaboratory variation based on average results per laboratory was statistically significant (P = 0⋅000). Based on mean values of all participating laboratories, a high LP-index was found for vaccine B (134⋅4) and E (144⋅8), while product D (57⋅1) showed a relative low LP-index. Heterogeneity of products was statistically significant at P Q 0⋅05. Interlaboratory analysis of variance of the 1/2 dilution results did not differ substantially from the undiluted results. 
Histamine Sensitization test (HS)
Data were received from four participants for all vaccines and from three laboratories for three vaccines. Products were only tested once, except laboratory 14 which performed the HS test in duplicate. Variation in test performance ( Table 5) was seen in the strain, number and initial weight of mice used, the challenge dose of histamine and the moment of reading after challenge. Overall interlaboratory variation in the highest vaccine dose was large (P = 0⋅098), but not statistically significant at P Q 0⋅05. Productsdiffered significantly at statistical analysis (P = 0⋅005). Product D and F appeared to be less reactogenic than the other products, while products C and E showed highest reactivity. HS values are plotted in Figure 3 for each vaccine at highest dose (1/5 diluted) and sub-highest dose (1/25 diluted); with the sub-highest vaccine dose a lower mortality rate was found. However, with regard to the vaccine reactivity, a similar picture emerged as for the highest dose group.
Chinese Hamster Ovary clustering test (CHO)
Data on CHO activity were received from five participants, except for vaccine F which was tested in three laboratories only. Test conditions varied ( Table 6 ) amongst others with regard to the concentration of CHO cells, the passage number and type of cell and the culture medium used. Data of the CHO test are shown Figure 4 . Heterogeneity of products, based on mean values of the responding laboratories, was found at statistical analysis (P = 0⋅000) at P Q 0⋅05. There was a marked interlaboratory variation (P = 0⋅000), statistically significant at P Q 0⋅05. Product B, E anf F appeared to be more reactogenic than product C which was used as ''reference preparation'', while product A and D were less toxic ( Fig. 4 ). Some participants reported that at low dilutions products were directly toxic to CHO-cells.
Limulus Amoebocyte Lysate endotoxin test (LAL)
Data were obtained from eight participants, apart from vaccine C and F which were tested in six and three laboratories, respectively. LAL values are presented in Endotoxin Units per ml. Significant differences in test performance were seen. Data of the LAL-test are visualized in Figure 5 , indicating that large variation occurred between the participants. Compared with other laboratories, very high values were obtained in laboratory 7 for product A and B. If this laboratory is excluded more uniform results are seen. In general, endotoxin levels were higher for vaccine A, B and E than for vaccine C and D. As some laboratories presented data as values ''greater than'', no statistical analysis could be performed.
Mouse Protection test according to Kendrick (MP)
Data on potency were obtained from 12 laboratories. Five participants examined all preparations, while the number of products tested in other laboratories ranged from two to five. From a number of tests data could not be used, as results were statistically invalid or the participant had used an own reference preparation. In general, potencies were assessed in duplicate. Vaccine E was used as a reference, although some of the participants used their own reference preparations. These results are excluded from the statistical analysis. Laboratories varied in their test performance with regard to the strain and weight of mice used, randomization of animals, challenge volume, challenge strain and preparation of culture conditions of the challenge strain. Vaccine potencies are shown in Table 9 . Estimates varied widely between the laboratories, for some products (vaccine A and B) up to 12-fold differences were observed. At statistical analysis interlaboratory variation (P = 0⋅004) was significant at P Q 0⋅05 when variance per test was used as a parameter but statistically non-significant (P = 0⋅158) when data of potencies were used without confidence intervals. Although duplicate testing within laboratories often revealed comparable estimates of potency, large differences were seen as well. From the data it can be seen that 95% confidence intervals were large, in particular those generated in laboratory 3 and 14. Mean estimates of potency for each vaccine, obtained in the various laboratories, are plotted in Figure 6 . In general for vaccine B and C potency values were higher than for vaccines A and D, although differences (P = 0⋅900) were not significant at statistical analysis (P Q 0⋅05).
Discussion
At the present time, B. pertussis is known to produce five toxins: HLT, PT, LPS, ACT and TCT. However, the exact role of these toxins in vaccine reactions remains unclear. This uncertainty has impeded the establishment of scientifically sound tests and permissible limits of residual activity of potentially toxic compounds.
For control of toxicity of whole cell pertussis vaccine, the Mouse Weight Gain test (MWG), originally developed to demonstrate HLT, is the only test currently accepted by EP 2 or US 3 requirements. Specifications have been given on the weight of the animals, route of injection and 53 Table 9 . Estimates of potency and their 95% confidence intervals: estimates calculated in terms of the International Standard and given in International Units per ampoule or per ml volume to be injected. In the collaborative study described above there was uniformity with regard to these specifications. However, participants' procedures varied in the strain and sex of animals used, the initial age of the animals and the vaccine dose administered. The effect of different strains of mice in their weight responses has been described before 4, 5, 6 and might be a reason for the 
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interlaboratory variation found in this study. As shown in Table 8 and Figure 1 , results varied widely between the participants in the assessment of the toxicity of the products. When ranking vaccines in order of weight gain (Table 10 ) product B, having high levels of PT was found to be most toxic, although differences between the vaccines were not statistically significant. Based on WHO 1 and EP 2 requirements, vaccine B, would have been classified as ''non-toxic'' in the MWG test in all participating laboratories apart from laboratory 5. It appeared that most animal strains used are not sufficiently sensitive to relative toxic vaccines, a finding which strongly questions the suitability of the MWG test for its intended purpose.
The main goal of the interlaboratory study described here was to evaluate the suitability of several bio-assay systems to assess specific aspects of whole-cell pertussis toxicity, being the LAL test for the assessment of LPS (endotoxin) and the CHO test, the LP test and the HS test for active pertussis toxin. Apart from the test in suckling mice no alternative tests systems are available to tests for heat-labile toxin. Therefore, this aspect of pertussis toxicity was not included in the collaborative study.
In evaluating the suitability of a test system as a model to assess specific aspects of pertussis toxicity, two aspects were considered to be of crucial importance; the precision (within and in-between laboratories) and the accuracy (the intrinsic capacity to discriminate in product quality or toxicity) of the test system.
The vaccines used in the collaborative study were selected to include products with varying levels of PT (as measured by PT binding ELISA) and International Units of potency. So vaccine B and C and E had high levels of PT and vaccine B and F were very potent products.
When relating the criteria of precision to each test system studied, it can be seen (Figs 1 to 5) that large variation in test results was found between the participating laboratories, statistically significant at P Q 0⋅05 for MWG test, LP test and CHO test, but not for HS test (P = 0⋅098).
At least three components, heat-labile (dermonecrotic) toxin, lipopolysaccharide (LPS, endotoxin) and PT (LP, HS) can influence the toxicity of whole-cell pertussis vaccine as measured by the mouse weight gain (MWG) test. 12, 13 Endotoxin induces a rise in body temperature at about one hour after vaccine injection 12 and weight loss which is confined to one day only, 13, 14 while other toxic substances of the micro-organism induce a fever reaction about 4 h after injection 12 and death and weight loss 2-3 days after inoculation which might continue until 14 days after inoculation. 13 Therefore it might be argued whether the MWG criteria used for weight gain at 72 h and 7 days, are suboptimal as the marked effects of toxicity are seen earlier post-immunization. With regard to LPS, the mouse body weight decreasing toxicity test, as laid down in the Japanese Minimum Requirements for Biological products, 15 might be a better tool to assess toxicity, as body weight is recorded 16 h post-injection. However, retrospective analysis of MWG data, performed at the co-ordinating laboratory did not show clear evidence to support this view.
Undoubtedly, a major source for test interlaboratory variation has been the low uniformity in test performance between the participating laboratories (Tables 4-6 ). Therefore, it is believed that variation can be reduced significantly by stringent standardization in test procedures, materials and test criteria. However, when the strain of animals is a major cause of variation, it might be very difficult to standardize the test systems for practical reasons only. It is known from HS test that sensitivity to the histamine-sensitizing activity of pertussis toxin is mouse strain dependent.
When considering the accuracy of the test systems, a distinction is made between the LAL test for endotoxin reactivity and the LP, HS and CHO tests for pertussis toxin activity. As no information is available about the LPS content of the products tested, it is not clear whether the results of the LAL test as indicated by the mean value reflect the real endotoxin toxicity of the product. It should be noted that whole cell pertussis vaccines have high endotoxin levels by nature and the LAL test is used mostly for low-titre products only. Some of the participating laboratories indicated that they had no experience with the use of the LAL test for high titre products. With regard to the test systems for PT toxicity, it was found that both LP-undiluted and LP-1/2 diluted, HS-1/25 diluted and CHO test, based on mean value of participating laboratories, identify product B as toxic. Contrary to HS test (1/5 and 1/25 diluted), the discriminative power of the LP test and CHO test was less pronounced for product C. Product E was classified as toxic in the LP test and to a lesser degree in HS (1/5 diluted) and CHO test. In all specific test systems, product D appeared to be the least toxic product. If products are classified in order of toxicity (Table 10 ) some relationship was observed between the test systems in that product B van Straaten-van de Kappelle et al. 56 was classified as a toxic product while product D was seen as relatively non-toxic. However, from the results given above, no conclusive answer can be given on the test system to be preferred in the evaluation of pertussis vaccine toxicity. Therefore, the classical MWG test seems to be inappropriate and insensitive, but no alternative test system for the assessment of whole-cell pertussis toxicity is available. The use of a modified model to estimate weight gain of mice at 16 hours and 7 days followed by bleeding and leukocyte count on day 7 might be worth studying. From the alternative models the LP test correlated well with the product toxicity known as it was the only test which identified the three products (B, C and E) with the highest levels of pertussis toxin. Also, the other test systems showed discriminative power and therefore should be considered for inclusion in quality control. However, further study is needed, in particular with regard to uniform test guidelines and test criteria. In this context, it should be noted that most participants used suboptimal conditions in the LP test, such as route of immunization. 16 The use of multi-dilution tests, e.g. LP and HS, might be questioned as no additional information was obtained in this collaborative study using more than one dilution. Further study is also of utmost importance as not the MWG test but one or more of the antigen-related test systems is likely to be included in the quality control of acellular pertussis vaccines. As can be seen in Table 7 , striking differences were seen in participants test specifications for the Mouse Protection test. This was reflected in interlaboratory consistency of estimates of potency. Tests of homogeneity applied to the sets of estimates of individual laboratories showed that variation between the laboratories was statistically significant at P Q 0⋅05. Differences in estimated potency between the laboratories often ranged from 4 to 5 and in a few occasions even more than a factor 10. This finding conflicts with the one of Seagroatt and Sheffield, 17 who found largely consistent data in all laboratories. Significant differences (up to factor 6) were also seen at intralaboratory duplicate testing. From the results (data not shown) there is no reason to believe that randomization within the test leads to more homogeneous test results as suggested by Redhead and Seagrout. 18 From the data generated in this study, one might conclude that a basic discussion on international standardization is urgently needed. As was shown in the MWG test and the MP test, standardized protocols and test guidelines as well as the inclusion of a reference preparation in the MP test did not rule out significant variability of test results. It might be anticipated that the strain of mice used has significantly attributed to test variability. A similar effect of the mouse strain used has also been described for potency testing on tetanus toxoid. 19, 20 Unfortunately, only limited information is available of laboratories using the same strain (and genotype) of mice. It must also be envisaged that for technical reasons, international standardization in animal use is an unrealistic and unreachable goal. Therefore, we believe that uniform guidelines and standardized test systems should be used to obtain in house consistency rather than to accomplish international standardization.
